Connect Biopharma (CNTB) Competitors $1.76 -0.02 (-1.12%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$1.76 +0.00 (+0.28%) As of 08/28/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNTB vs. CRVS, KMDA, AURA, IMAB, YMAB, AQST, VIGL, OLMA, RCKT, and ZYBTShould you be buying Connect Biopharma stock or one of its competitors? The main competitors of Connect Biopharma include Corvus Pharmaceuticals (CRVS), Kamada (KMDA), Aura Biosciences (AURA), I-Mab (IMAB), Y-mAbs Therapeutics (YMAB), Aquestive Therapeutics (AQST), Vigil Neuroscience (VIGL), Olema Pharmaceuticals (OLMA), Rocket Pharmaceuticals (RCKT), and Zhengye Biotechnology (ZYBT). These companies are all part of the "pharmaceutical products" industry. Connect Biopharma vs. Its Competitors Corvus Pharmaceuticals Kamada Aura Biosciences I-Mab Y-mAbs Therapeutics Aquestive Therapeutics Vigil Neuroscience Olema Pharmaceuticals Rocket Pharmaceuticals Zhengye Biotechnology Corvus Pharmaceuticals (NASDAQ:CRVS) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends. Does the media favor CRVS or CNTB? In the previous week, Connect Biopharma had 3 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 5 mentions for Connect Biopharma and 2 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.62 beat Connect Biopharma's score of 0.49 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Connect Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, CRVS or CNTB? Corvus Pharmaceuticals has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.09, suggesting that its stock price is 109% less volatile than the S&P 500. Which has higher earnings & valuation, CRVS or CNTB? Connect Biopharma has higher revenue and earnings than Corvus Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorvus PharmaceuticalsN/AN/A-$62.29M-$1.01-5.36Connect Biopharma$26.03M3.77-$15.63MN/AN/A Do analysts recommend CRVS or CNTB? Corvus Pharmaceuticals presently has a consensus target price of $15.00, suggesting a potential upside of 177.26%. Connect Biopharma has a consensus target price of $7.00, suggesting a potential upside of 297.73%. Given Connect Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Connect Biopharma is more favorable than Corvus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corvus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Connect Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Is CRVS or CNTB more profitable? Connect Biopharma's return on equity of 0.00% beat Corvus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Corvus PharmaceuticalsN/A -28.61% -18.05% Connect Biopharma N/A N/A N/A Do institutionals and insiders hold more shares of CRVS or CNTB? 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are held by institutional investors. 28.5% of Corvus Pharmaceuticals shares are held by company insiders. Comparatively, 22.6% of Connect Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryConnect Biopharma beats Corvus Pharmaceuticals on 9 of the 13 factors compared between the two stocks. Get Connect Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CNTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNTB vs. The Competition Export to ExcelMetricConnect BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$99.18M$3.10B$5.78B$9.79BDividend YieldN/A2.26%3.95%4.02%P/E RatioN/A21.0831.2726.59Price / Sales3.77349.55428.42155.72Price / CashN/A44.6737.7359.36Price / Book1.388.0910.046.68Net Income-$15.63M-$54.08M$3.27B$265.59M7 Day Performance-3.83%-0.41%1.34%0.66%1 Month Performance0.57%6.23%6.13%2.64%1 Year Performance37.50%10.45%41.90%22.36% Connect Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNTBConnect Biopharma3.3479 of 5 stars$1.76-1.1%$7.00+297.7%+72.5%$99.18M$26.03M0.00110Upcoming EarningsGap DownCRVSCorvus Pharmaceuticals3.222 of 5 stars$5.45-1.8%$15.00+175.2%+32.0%$406.10MN/A-5.4030KMDAKamada4.7542 of 5 stars$7.05-1.8%$13.00+84.4%+22.7%$405.45M$160.95M20.74360AURAAura Biosciences1.7156 of 5 stars$6.52-0.5%$22.00+237.4%-16.8%$405.02MN/A-3.3350IMABI-Mab2.9948 of 5 stars$4.82-5.3%$6.50+34.9%+263.2%$393.60M$3.89M0.00380Analyst ForecastHigh Trading VolumeYMABY-mAbs Therapeutics2.6796 of 5 stars$8.52-0.1%$9.62+12.9%-44.5%$387.13M$85.39M-17.04150AQSTAquestive Therapeutics2.2462 of 5 stars$3.86-3.0%$10.14+162.8%-15.8%$384.94M$44.13M-5.51160Positive NewsVIGLVigil Neuroscience1.783 of 5 stars$8.05flat$10.80+34.2%N/A$383.91MN/A-3.9340OLMAOlema Pharmaceuticals1.9484 of 5 stars$5.59-3.0%$24.00+329.3%-51.7%$383.64MN/A-2.8270Positive NewsRCKTRocket Pharmaceuticals4.908 of 5 stars$3.54-2.7%$16.73+372.7%-81.9%$381.98MN/A-1.41240ZYBTZhengye BiotechnologyN/A$8.00+14.6%N/AN/A$377.36M$25.53M0.00278News CoveragePositive NewsGap Up Related Companies and Tools Related Companies CRVS Competitors KMDA Competitors AURA Competitors IMAB Competitors YMAB Competitors AQST Competitors VIGL Competitors OLMA Competitors RCKT Competitors ZYBT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNTB) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Connect Biopharma Holdings Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Connect Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access